Show simple item record

dc.contributor.authorHaraldsdóttir, Kristín-Huld
dc.contributor.authorIngvar, Christian
dc.contributor.authorStenram, Unne
dc.contributor.authorTranberg, Karl-Göran
dc.date.accessioned2016-01-04T13:27:44Zen
dc.date.available2016-01-04T13:27:44Zen
dc.date.issued2015-11en
dc.date.submitted2015en
dc.identifier.citationLong-term Follow-up After Interstitial Laser Thermotherapy of Breast Cancer. 2015, 35 (11):6147-52 Anticancer Res.en
dc.identifier.issn1791-7530en
dc.identifier.pmid26504041en
dc.identifier.urihttp://hdl.handle.net/2336/592767en
dc.descriptionTo access publisher's full text version of this article click on the hyperlink at the bottom of the pageen
dc.description.abstractTo review the effect of immunological changes induced by interstitial laser thermotherapy (ILT) on long-term outcome of patients with breast cancer.
dc.description.abstractTwenty-four patients with invasive breast cancer were treated with ILT followed by standard surgical excision. Immunohistological reactions on immunocompetent cells were performed on specimens obtained before and after ILT. Follow-up time was 116 (range=91-136) months.
dc.description.abstractSignificant prognostic factors were histologically-positive axillary lymph nodes and Ki67 positivity. ILT increased cytotoxic T (CD8(+)) lymphocytes within the tumor and mature dendritic cells (CD83(+)) and reduced the number of T-regulatory cells (Treg) CD25(+)/Forkhead box p3(+) (FOXP3(+)) lymphocytes in regional lymph nodes. These changes did not correlate with prognosis. The number of CD8(+) cells within the tumor, both before and after treatment, was significantly higher in patients with recurrence than in those without recurrence (p<0.01 and p<0.05, respectively). Patients with recurrent disease had a lower number of CD57(+) cells in tumor-free lymph nodes than did patients without recurrence (p<0.05).
dc.description.abstractILT did not have any long-term adverse effects. The clinical impact of the supposedly favourable immune changes after ILT should be examined in a larger patient population.
dc.description.sponsorshipSwedish Cancer Society Crafoord Foundation Lund University Hospital Lundgren Foundation GAE Nilsson Foundation for Cancer Treatment John and Augusta Persson Foundation for Scientific Medical Research Royal Physiographic Society in Lunden
dc.language.isoenen
dc.publisherInt Inst Anticancer Researchen
dc.rightsArchived with thanks to Anticancer researchen
dc.subjectBrjóstakrabbameinen
dc.subject.meshBreast Neoplasmsen
dc.subject.meshaser Therapyen
dc.subject.meshLymph Nodesen
dc.titleLong-term Follow-up After Interstitial Laser Thermotherapy of Breast Cancer.en
dc.typeArticleen
dc.contributor.department[ 1 ] Lund Univ, Dept Surg, Lund, Sweden [ 2 ] Lund Univ, Dept Pathol, Lund, Sweden [ 3 ] Univ Lund Hosp, S-22185 Lund, Sweden, [ 4 ]Landspitali Univ Hosp, Dept Surgen
dc.identifier.journalAnticancer researchen
dc.rights.accessClosed - Lokaðen
html.description.abstractTo review the effect of immunological changes induced by interstitial laser thermotherapy (ILT) on long-term outcome of patients with breast cancer.
html.description.abstractTwenty-four patients with invasive breast cancer were treated with ILT followed by standard surgical excision. Immunohistological reactions on immunocompetent cells were performed on specimens obtained before and after ILT. Follow-up time was 116 (range=91-136) months.
html.description.abstractSignificant prognostic factors were histologically-positive axillary lymph nodes and Ki67 positivity. ILT increased cytotoxic T (CD8(+)) lymphocytes within the tumor and mature dendritic cells (CD83(+)) and reduced the number of T-regulatory cells (Treg) CD25(+)/Forkhead box p3(+) (FOXP3(+)) lymphocytes in regional lymph nodes. These changes did not correlate with prognosis. The number of CD8(+) cells within the tumor, both before and after treatment, was significantly higher in patients with recurrence than in those without recurrence (p<0.01 and p<0.05, respectively). Patients with recurrent disease had a lower number of CD57(+) cells in tumor-free lymph nodes than did patients without recurrence (p<0.05).
html.description.abstractILT did not have any long-term adverse effects. The clinical impact of the supposedly favourable immune changes after ILT should be examined in a larger patient population.


This item appears in the following Collection(s)

Show simple item record